HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Wuhan YZY Biopharma / Equity Capital Markets

<ul>
<li>YZY is a company that is serious about drug development However, there is actually high R&amp;D risk of its pipeline candidates. So, YZY’s R&amp;D capability has yet to be proven.</li>
<li>There are still many unanswered questions in the whole direction of bispecific antibody. If YZY’s candidates fail to prove better marginal clinical benefits, they won’t have good commercialization performance. </li>
<li>YZY has a long way to go based on its pipeline situation. Considering <a href="https://www.smartkarma.com/entities/wuhan-yzy-biopharma-co-ltd" target="_blank" data-smartkarma-citation="entities:36600:1" rel="noopener">Wuhan YZY Biopharma (YZY HK)</a> has no product in commercialization stage, its valuation may not be high.</li>
</ul>


YZY is a company that is serious about drug development However, there is actually high R&amp;D risk of its pipeline candidates. So, YZY’s R&amp;D capability has yet to be proven.
There are still many unanswered questions in the whole direction of bispecific antibody. If YZY’s candidates fail to prove better marginal clinical benefits, they won’t have good commercialization performance. 
YZY has a long way to go based on its pipeline situation. Considering Wuhan YZY Biopharma (YZY HK) has no product in commercialization stage, its valuation may not be high.


Pre-IPO Wuhan YZY Biopharma - Both R&D and Commercialization Capabilities Have yet to Be Proven

China

YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies.

Pre-IPO Wuhan YZY Biopharma - Both R&D and Commercialization Capabilities Have yet to Be Proven

YZY passed the hearing of HKEX. We've analyzed its business, pipeline and concerns in this insight. It should be pointed out that investors have...

Xinyao (Criss) Wang